Stroke Prevention in
Atrial Fibrillation

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium:

Internet-based program

Method of Physician Participation Utilized in Learning Process:

There are no fees for participating and receiving CME credit for this activity. During the period December 21, 2010 through December 21, 2012 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) register and complete the evaluation form; and 4) print out your CME certificate.

Estimated Time to Complete Educational Activity:

3.0 hours

Course Overview:

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in the prevention of stroke in the setting of atrial fibrillation.

Release Date:

December 21, 2010

Expiration Date:

December 21, 2012

Intended Audience:

• Cardiologists
• Preventive cardiologists
• Cardiovascular electrophysiologists
• Neurovascular specialists
• Vascular biologists
• Anticoagulation experts
• Heart failure specialists
• Coronary care unit (CCU) specialists and directors
• Program directors, cardiovascular medicine
• Fellows in cardiovascular medicine
• Clinical pharmacists and pharmacologists
• Pharmacy directors (cardiovascular medicine)
• Investigators and clinical trial specialists
• Cardiovascular nurses

Registration:

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

Supported by an Independent
Educational Grant
from Boehringer Ingelheim

Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Massachusetts Medical School and CMEducation Resources, LLC. University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

University of Massachusetts Medical School designates this educational activity for a maximum of 3.0 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure:

It is the policy of University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosures:

Program Chairman
Samuel Z. Goldhaber, MD
Professor of Medicine
Director, Venous Thromboembolism Research Unit
Brigham and Women's Hospital
Harvard Medical School
Boston, MA

Advisor or consultant: Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Eisai, and sanofi-aventis.
Research support: Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Eisai, Johnson & Johnson Pharmaceutical Research & Development and sanofi-aventis

Jonathan L. Halperin, MD
Professor of Medicine (Cardiology)
Mount Sinai School of Medicine
Director, Clinical Cardiology Services
The Zena and Michael A. Weiner Cardiovascular Institute
The Marie-Josée and Henry R. Kravis Center for Cardiovascular Health
New York, NY

Consultant: Astellas Pharma, U.S., Bayer Healthcare, Biotronik, Inc., Boehringer Ingelheim, Daiichi Sankyo Pharma, J&J, Sanofi-Aventis


Elaine M. Hylek, MD, MPH
Associate Professor of Medicine
Department of Medicine
Boston University Medical Center
Boston, MA

Consultant: Boehringer Ingelheim, Bayer, Bristol-Myers Squibb, Daiichi Sankyo, Merck
Grant/Research Support: Ortho-McNeil


David A. Garcia, MD
Associate Professor, Division of General Internal Medicine
University of New Mexico
Co-Director, University of New Mexico Anticoagulation Management Service
President, Anticoagulation Forum
Albuquerque, NM

Consultant: Boehringer Ingelheim, Bristol-Myers Squibb, Ortho-McNeil-Janssen
Grant/Research Support: Bristol-Myers Squibb


Jeffrey I. Weitz, MD, FRCP, FACP
Professor of Medicine and Biochemistry
McMaster University
Director, Henderson Research Center
Canada Research Chair in Thrombosis
Heart and Stroke Foundation
J.F. Mustard Chair in Cardiovascular Research
Hamilton, Ontario, Canada

Consultant: BMS, Boehringer Ingelheim, Daiichi Sankyo Pharma, Bayer, Pfizer, Takeda, Sanofi- Aventis, The Medicines Company

Program Managers and Web Editor Disclosure:

Program Manager Gideon Bosker, MD has nothing to disclose.

Program Reviewers Denise Leary and Richard Aghababian, MD have nothing to disclose.

Educational Objectives:

Upon Completion of this Health Management Session, Participants Should Be Able To:

• Discuss the evidence basis and clinical implications of the evolving, multidimensional landscape for anticoagulation-based management in chronic AF.
• Understand and apply evidence-based, risk-specific interventions across the comprehensive (low, moderate, and high risk) spectrum of patient subgroups with AF.
• Risk stratify patients with atrial fibrillation (AF) in order to determine guideline-consistent and risk-specific treatment based on age, comorbid features, risks and benefits or anticoagulation therapy.
• Optimize residual stroke risk reduction in AF in low-, moderate-, and high-risk patient populations, and how to employ the CHADS risk stratification tool to assist selection of therapies for AF.
• Analyze late-breaking landmark clinical trials focusing on thromboembolic risk prevention in patients with atrial fibrillation.
• Apply current guidelines issued by national professional organizations and colleges, such as the AHA, ACC, AAN, and others mandating risk-directed prophylaxis against arterial thrombosis in the setting of heart disease.
  
  
  

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to printout the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

• We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
• For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
• We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
• If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
• You should check this privacy policy periodically to see whether we have made any changes.
  
  

Disclaimer:

Copyright © 2011 Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright © 2011 Resources, LLC All rights reserved.